Nanomedicine Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Nanomedicine stocks.

Nanomedicine Stocks Recent News

Date Stock Title
May 21 AZN AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
May 20 AZN Pfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute
May 20 AZN Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
May 20 AZN AstraZeneca, Amgen release mid-stage data on Tezspire for COPD
May 20 AZN AstraZeneca to build $1.5B ADC manufacturing plant in Singapore
May 20 AZN AstraZeneca (AZN) to Build $1.5B Cancer Drug Plant in Singapore
May 20 AZN Trending tickers: Gold, Ryanair, Nvidia and AstraZeneca
May 20 AZN AstraZeneca to build $1.5bn ADCs facility in Singapore
May 20 AZN Pfizer wins cancer drug patent case against AstraZeneca
May 20 AZN AstraZeneca Plans $1.5 Billion Manufacturing Facility In Singapore
May 19 AZN New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
May 19 AZN Biopharma M&A surges year over year in Q1
May 17 AZN Puma Biotech pares gain amid Wyeth victory in Tagrisso patent case against AstraZeneca
May 17 AZN AstraZeneca’s Phase III Covid-19 antibody trial meets primary endpoints
May 16 AZN AstraZeneca's COVID-19 Prevention Therapy Cuts Risk Of Infection In Patients With Weaker Immunity, Data Shows
May 16 AZN Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
May 16 AZN AstraZeneca COVID therapy succeeds in late-stage study for the vulnerable
May 16 AZN AstraZeneca selects new heart failure target with BenevolentAI
May 15 NBTX NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024
May 14 NBTX NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer
Nanomedicine

Nanomedicine is the medical application of nanotechnology. Nanomedicine ranges from the medical applications of nanomaterials and biological devices, to nanoelectronic biosensors, and even possible future applications of molecular nanotechnology such as biological machines. Current problems for nanomedicine involve understanding the issues related to toxicity and environmental impact of nanoscale materials (materials whose structure is on the scale of nanometers, i.e. billionths of a meter).Functionalities can be added to nanomaterials by interfacing them with biological molecules or structures. The size of nanomaterials is similar to that of most biological molecules and structures; therefore, nanomaterials can be useful for both in vivo and in vitro biomedical research and applications. Thus far, the integration of nanomaterials with biology has led to the development of diagnostic devices, contrast agents, analytical tools, physical therapy applications, and drug delivery vehicles.
Nanomedicine seeks to deliver a valuable set of research tools and clinically useful devices in the near future. The National Nanotechnology Initiative expects new commercial applications in the pharmaceutical industry that may include advanced drug delivery systems, new therapies, and in vivo imaging. Nanomedicine research is receiving funding from the US National Institutes of Health Common Fund program, supporting four nanomedicine development centers.Nanomedicine sales reached $16 billion in 2015, with a minimum of $3.8 billion in nanotechnology R&D being invested every year. Global funding for emerging nanotechnology increased by 45% per year in recent years, with product sales exceeding $1 trillion in 2013. As the nanomedicine industry continues to grow, it is expected to have a significant impact on the economy.

Browse All Tags